Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease.

Whereas much research has investigated equations for obtaining estimated GFR (eGFR) from serum creatinine in cross-sectional settings, little attention has been given to validating these equations as outcomes in longitudinal studies of chronic kidney disease. A common objective of chronic kidney disease studies is to identify risk factors for progression, characterized by slope (rate of change over time) or time to event (time until a designated decline in kidney function or ESRD). The relationships of 35 baseline factors with eGFR-based outcomes were compared with the relationships of the same factors with iothalamate GFR (iGFR)-based outcomes in the African American Study of Kidney Disease and Hypertension (AASK; n = 1094). With the use of the AASK equation to calculate eGFR, results were compared between time to halving of eGFR or ESRD and time to halving of iGFR or ESRD (with effect sizes expressed per 1 SD) and between eGFR and iGFR slopes starting 3 mo after randomization. The effects of the baseline factors were similar between the eGFR- and iGFR-based time-to-event outcomes (Pearson R = 0.99, concordance R = 0.98). Small but statistically significant differences (P < 0.05, without adjustment for multiple analyses) were observed for seven of the 35 factors. Agreement between eGFR and iGFR was somewhat weaker, although still relatively high for slope-based outcomes (Pearson R = 0.93, concordance R = 0.92). Effects of covariate adjustment for age, gender, baseline GFR, and urine proteinuria also were similar between the eGFR and iGFR outcomes. Sensitivity analyses including death in the composite time-to-event outcomes or using the Modification of Diet in Renal Disease equation instead of the AASK equation provided similar results. In conclusion, the data from the AASK provide tentative support for use of outcomes that are based on an established eGFR formula using serum creatinine as a surrogate for measured iGFR-based outcomes in analyses of risk factors for the progression of kidney disease.

[1]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy , 2002 .

[2]  Hai‐yan Wang,et al.  Application of GFR-estimating equations in Chinese patients with chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  R. Schrier.  Diseases of the Kidney and Urinary Tract , 2001 .

[4]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[5]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[6]  N. Madias,et al.  Serum creatinine as an index of renal function: new insights into old concepts. , 1992, Clinical chemistry.

[7]  Geert Molenberghs,et al.  Evaluation of Surrogate Endpoints , 2006, Handbook of Statistical Methods for Randomized Controlled Trials.

[8]  G. Navis,et al.  Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[10]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[11]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[12]  Keith C. Norris,et al.  The rationale and design of the AASK cohort study. , 2003, Journal of the American Society of Nephrology : JASN.

[13]  D. Riley,et al.  Prediction of GFR in liver transplant candidates. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  P. Grambsch,et al.  Multiple Events per Subject , 2000 .

[15]  Homer W. Smith.  The Kidney: Structure and Function in Health and Disease , 1952 .

[16]  T. Larson,et al.  Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease , 2004, Annals of Internal Medicine.

[17]  F. Kronenberg,et al.  Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  C. Perlemoine,et al.  Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation? , 2005, Diabetes care.

[19]  A. Levey,et al.  Measurement of renal function in chronic renal disease. , 1990, Kidney international.

[20]  N. Perico,et al.  Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[22]  J. Wetzels,et al.  Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[24]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[25]  T. Greene,et al.  Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.

[26]  C. Edelmann,et al.  Diseases of the kidney and urinary tract , 1992 .

[27]  Ana Ivelisse Avilés,et al.  Linear Mixed Models for Longitudinal Data , 2001, Technometrics.

[28]  S. Hallan,et al.  Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[30]  G. Dunea.  Immunologic Renal Disease , 1997 .

[31]  G. Bakris,et al.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.

[32]  Jacob Cohen.  A Coefficient of Agreement for Nominal Scales , 1960 .

[33]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[34]  L. Appel,et al.  A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. , 2004, Journal of the American Society of Nephrology : JASN.

[35]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[36]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[37]  J. Lewis,et al.  Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Geert Molenberghs,et al.  A Meta-analytic Validation Framework for Continuous Outcomes , 2005 .

[39]  P. Houillier,et al.  Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. , 2005, Journal of the American Society of Nephrology : JASN.

[40]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[41]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[42]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[43]  Keith C. Norris,et al.  Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. , 2006, Journal of the American Society of Nephrology : JASN.

[44]  M. Kutner,et al.  Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). , 2003, Journal of the American Society of Nephrology : JASN.

[45]  Ajay K. Singh,et al.  A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. , 2003, Journal of the American Society of Nephrology : JASN.